يبحث (أخبار)

PolyPid Advances D-PLEX100; FDA Grants Priority Review

english business

PolyPid (PYPD) received FDA Priority Review for D-PLEX100, with a PDUFA goal date of November 28, 2026. The company also secured a U.S. and Canada commercialization partnership with Azurity, triggering $30M in upfront and near-term milestones.
2026-08-12 18:45:15